摘要:
The present invention relates to treating/preventing conditions associated with an increased level of eotaxin in a human with 25-hydroxyvitamin D3 (calcifediol). Optionally, vitamin D3 may be used together with 25-hydroxyvitamin D3.
摘要:
The use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both is provided. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.
摘要:
We disclose compositions comprising Vitamin D (cholecalciferol and/or ergocalciferol) and 25-OH D3 (calcifediol), and use of those compositions to affect at least concentration, bioavailability, metabolism, or efficacy of vitamin D in a human. Forms and dosages of the composition, as well as processes for manufacturing a spray-dried formulation, are also disclosed.
摘要:
We disclose compositions comprising Vitamin D (cholecalciferol and/or ergocalciferol) and 25-OH D3 (calcifediol), and use of those compositions to affect at least concentration, bioavailability, metabolism, or efficacy of vitamin D in a human. Forms and dosages of the composition, as well as processes for manufacturing a spray-dried formulation, are also disclosed.
摘要:
Biologically active compounds (e.g. from the groups of pharmaceutical drugs, cofactors, hormones, vitamins or phytochemicals) often consist of two or more stereoisomers (enantiomers or diastereoisomers) which may differ in their pharmacodynamic/kinetic, toxicological and biological properties. These differences are so far difficult to detect. A well known example for a biologically active compound and its counterpart is vitamin E which is predominantly administered as two different ‘forms’, one derived from natural sources (mainly soybeans), and one from production by chemical total-synthesis. While vitamin E from natural sources occurs as a single stereoisomer (RRR-α-tocopherol), so-called synthetic vitamin E (all-rac-α-tocopherol) is an equimolar mixture of eight stereoisomers. The present invention is directed to a method for calculating the biological activity of a biologically active compound (e.g. RRR-α-tocopherol) and a counterpart thereof (e.g. all-rac-α-tocopherol), comprising the steps of: culturing a plurality of cells in a culture medium and treating the cells with different concentrations of either said compound or said counterpart thereof; or treating a plurality of animals or plants with different concentrations of either said compound or said counterpart; preparing samples from the treated cells or animals or plants containing a pool of target nucleic acids comprising RNA transcripts; detecting the expression of genes in said cells by measuring the amount of transcripts of said genes to obtain a target expression pattern by hybridizing said pool of target nucleic acids to an array of nucleic acid probes immobilized on a surface, wherein said array comprising at least 10 different nucleic acids, some of which comprise control probes, and wherein each different nucleic acid is localized in a known location of said surface; quantifying the hybridization of said nucleic acids to said array by comparing binding of matched and control probes; calculating the biological activity of the compound and its counterpart therefrom.
摘要:
We disclose the use of optionally in combination with vitamin D3 (cholecalciferol), 25-hydroxyvitamin D3 (cal-cifediol), to treat hypertension. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.
摘要:
We disclose the combined use of vitamin D (cholecalciferol) and 25-OH D3 (calcifediol) to treat and/or prevent osteoporosis. One or more bisphosphonate compounds to inhibit bone resorption may also be used. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.